A5006500101- SARS-CoV-2 and COVID-19 Research
- Poxvirus research and outbreaks
- COVID-19 Clinical Research Studies
- Herpesvirus Infections and Treatments
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Mosquito-borne diseases and control
- Bacillus and Francisella bacterial research
- Immunotherapy and Immune Responses
- SARS-CoV-2 detection and testing
- Long-Term Effects of COVID-19
- Respiratory viral infections research
- Lysosomal Storage Disorders Research
- vaccines and immunoinformatics approaches
- Viral Infections and Vectors
- HIV Research and Treatment
- interferon and immune responses
- Monoclonal and Polyclonal Antibodies Research
- Advanced biosensing and bioanalysis techniques
- Sphingolipid Metabolism and Signaling
- Virus-based gene therapy research
- COVID-19 and healthcare impacts
- RNA and protein synthesis mechanisms
- Influenza Virus Research Studies
- Lipid Membrane Structure and Behavior
Israel Institute for Biological Research
2014-2025
Institute for Biological Sciences
2021
Tel Aviv University
2001
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of ongoing disease 2019 (COVID-19) pandemic1. To understand pathogenicity and antigenic potential SARS-CoV-2 to develop therapeutic tools, it essential profile full repertoire its expressed proteins. The current map coding capacity based on computational predictions relies homology with other coronaviruses. As protein complement varies among coronaviruses, especially in regard variety accessory proteins, crucial...
We report a case of monkeypox in man who returned from Nigeria to Israel 2018. Virus was detected pustule swabs by transmission electron microscopy and PCR confirmed immunofluorescence assay, tissue culture, ELISA. The West Africa outbreak calls for increased awareness public health authorities worldwide.
Abstract The COVID-19 pandemic caused by SARS-CoV-2 imposes an urgent need for rapid development of efficient and cost-effective vaccine, suitable mass immunization. Here, we show the a replication competent recombinant VSV-∆G-spike in which glycoprotein VSV is replaced spike protein SARS-CoV-2. In-vitro characterization this vaccine indicates expression presentation on viral membrane with antigenic similarity to A golden Syrian hamster in-vivo model implemented. We that single-dose...
Abstract The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of COVID-19 pandemic. Thus far, there no approved therapeutic drug specifically targeting this emerging virus. Here we report isolation and characterization a panel neutralizing monoclonal antibodies receptor binding domain (RBD). These were selected from phage display library constructed using peripheral circulatory lymphocytes collected patients at acute phase disease. are shown to recognize...
We report the results of COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease. discovered noncovalent, nonpeptidic inhibitor scaffold with lead-like properties that is differentiated from current protease inhibitors. Our approach leveraged crowdsourcing, machine learning, exascale molecular simulations, high-throughput structural biology chemistry. generated...
Environmental surfaces have been suggested as likely contributors in the transmission of COVID-19. This study assessed infectivity severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contaminating and objects two hospital isolation units a quarantine hotel.
The current monkeypox virus global spread and lack of data regarding clinical specimens’ infectivity call for examining infectivity, whether this correlates with results from PCR, the available diagnostic tool. We show strong correlation between viral DNA amount in specimens toward BSC-1 cell line. Moreover, we define a PCR threshold value (Cq ≥ 35, ≤ 4,300 copies/mL), corresponding to negative cultures, which may assist risk-assessment decision-making protective-measures guidelines patients...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of ongoing disease 2019 (COVID-19) pandemic. The continued spread SARS-CoV-2 increases probability influenza/SARS-CoV-2 coinfection, which may result in severe disease. In this study, we examine outcome influenza A virus (IAV) and coinfection K18-hACE2 mice. Our data indicate enhance susceptibility IAV-infected mice to developing upon with two days later. contrast nonfatal lower mortality rates due alone,...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to shutoff of protein synthesis, and nsp1, a central factor in coronaviruses, inhibits cellular mRNA translation. However, the diverse molecular mechanisms employed by nsp1 as well its functional importance are unresolved. By overexpressing various mutants generating SARS-CoV-2 mutant, we show that through inhibition translation induction degradation, targets translated is main driver host during infection. The propagation...
Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome 2 (SARS-CoV-2), exhibits high levels of mortality and morbidity has dramatic consequences on human life, sociality global economy. Neutralizing antibodies constitute a highly promising approach for treating preventing infection this novel pathogen. In present study, we characterize further evaluate recently identified monoclonal MD65 antibody its ability to provide protection against...
Monkeypox virus (MPXV) resides in two forms; mature and enveloped, depending on it, distinct proteins are displayed the viral surface. Here, we expressed MPXV antigens from mature, one enveloped form, tested their reactivity to sera of 11 recoverees while comparing recently past vaccinated individuals. 8 out exhibited detectable neutralization levels against Vaccinia Lister. Sera all bound strongly A35R H3L antigens. Moreover, responses were significantly higher within compared both donors....
BackgroundWe assessed outcome of patients with moderate and severe COVID-19 following treatment convalescent plasma (CP) the association IgG levels in transfused CP.MethodsA prospective cohort study. Primary was improvement at day 14 defined as alive, not on mechanical ventilation, moderate, mild, or recovered from COVID-19. Antibody CP units were unknown time treatment. against spike protein S1 subsequently measured by ELISA. Neutralizing antibodies titers determined a subset. Outcome...
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of ongoing Coronavirus disease 19 (COVID-19) pandemic 1,2 . In order to understand SARS-CoV-2 pathogenicity and antigenic potential, develop diagnostic therapeutic tools, it essential portray full repertoire its expressed proteins. The coding capacity map currently based on computational predictions relies homology other coronaviruses. Since coronaviruses differ in their protein array, especially variety...
Public health experts emphasize the need for quick, point-of-care SARS-CoV-2 detection as an effective strategy controlling virus spread. To this end, many "antigen" devices were developed and commercialized. These are mostly based on detecting SARS-CoV-2's nucleocapsid protein. Recently, alerts issued by both FDA CDC raised concerns regarding devices' tendency to exhibit false positive results. In work, we a novel alternative spike-based antigen assay, comprising four high-affinity,...
The global spread of SARS-CoV-2 led to major economic and health challenges worldwide. Revealing host genes essential for infection by multiple variants can provide insights into the virus pathogenesis, facilitate development novel therapeutics. Here, employing a genome-scale CRISPR screen, we comprehensive data-set cellular factors that are exploited wild type as well two additional recently emerged concerns (VOCs), Alpha Beta. We identified several critical infection, including various...
SARS-CoV-2, a member of the coronavirus family, is causative agent COVID-19 pandemic. Currently, there still an urgent need in developing efficient therapeutic intervention. In this study, we aimed at evaluating effect single intranasal treatment TLR3/MDA5 synthetic agonist Poly(I:C) against lethal dose SARS-CoV-2 K18-hACE2 transgenic mice. We demonstrate here that early acts synergistically with to induce intense, immediate and transient upregulation innate immunity-related genes lungs....
Abstract The eradication of smallpox was officially declared by the WHO in 1980, leading to discontinuation vaccination campaign against virus. Consequently, immunity and related orthopoxviruses like Monkeypox virus gradually declines, highlighting need for efficient countermeasures not only prevention, but also treatment already exposed individuals. We have recently developed human-like monoclonal antibodies (mAbs) from vaccinia virus-immunized non-human primates. Two mAbs, MV33 EV42,...
Vibrio shiloi, the causative agent of bleaching coral Oculina patagonica in Mediterranean Sea, adheres to its host by a β-d-galactopyranoside-containing receptor on surface. The is present mucus, since V. shiloi adhered avidly mucus-coated ELISA plates. Adhesion was inhibited methyl-β-d-galactopyranoside. Removal mucus from O. resulted delay adhesion coral, corresponding regeneration mucus. DCMU recovery bacteria mucus-depleted corals, indicating that active photosynthesis endosymbiotic...
The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health. Vaccines are ideal solutions prevent infection, but treatments also needed for those who have contracted the virus limit negative outcomes, when vaccines not applicable. Viruses must cross host cell membranes during their life cycle, creating dependency on processes involving membrane dynamics. Thus, in this study, we examined whether synthetic machinery...
Understanding pathways that might impact coronavirus disease 2019 (COVID-19) manifestations and outcomes is necessary for better management therapeutic development. Here, we analyzed alterations in sphingolipid (SL) levels upon infection with severe acute respiratory syndrome 2 (SARS-CoV-2). SARS-CoV-2 induced elevation of SL both cells sera infected mice. A significant increase glycosphingolipid was early post infection, which essential viral replication. This could be reversed by treatment...
Although coronavirus disease 2019 (COVID-19) causes significan t morbidity, mainly from pulmonary involvement, extrapulmonary symptoms are also major componen ts of the disease. Kidney disease, usually presenting as AKI, is particularly severe among patients with COVID-19. It unknown, however, whether such injury results direct kidney infection COVID-19's causative virus, acute respiratory syndrome 2 (SARS-CoV-2), or indirect mechanisms.
The emergence of rapidly spreading variants severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability vaccines and therapeutic antibodies provide immunity. These contain mutations specific amino acids that might impede vaccine efficacy. BriLife